

Docket No.: 217415US0PCT

DT05.R PCT/PTO

OBLON Spivak

McClelland

MAIER

NEUSTADT

P.C.

ATTORNEYS AT LAW

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 202315

RE: Application Serial No.: 10/019,439

Applicants: Guy SERRE, et al.

Filing Date: May 8, 2002

For: FIBRIN CITRULLINE DERIVATIVES AND THEIR

USE FOR DIAGNOSING OR TREATING

RHEUMATOID ARTHRITIS

SIR:

Attached hereto for filing are the following papers:

Preliminary Amendment and Statement w/Marked-Up Copy (5 pp.); Sequence Listing Paper (1 page); Sequence Listing Computer Readable Form (CRF) Diskette; Return Copy – Notification of Missing Requirements Under 35 U.S.C. 371 in the U.S. Designated/Elected Office (DO/EO/US)

Our check in the amount of **\$0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, MCCLELLAND,

MAIER & NEUSTADZ,

Norman F. Oblon

Registration No. 24,618

James J. Kelly, Ph.D. Registration No. 41,504

22850

(703) 413-3000 (phone) (703) 413-2220 (fax)



## UNITED STATES PATENT AND TRADEMARK OFFICE

Consensationer for Patients, Box PCI United States Patient and Trademark Office Washington, C.C., 29233

| U.S. APPLICATION NUMBER NO.                          | FIRST NAMED APPLICANT | ATT              | Y. DOCKET NO.                 |  |
|--|-----------------------|------------------|-------------------------------|--|
| 10/019,439 Guy Serre                                 |                       | 217415US0PCT     |                               |  |
|  |                       | INTERNATIONAL AP | INTERNATIONAL APPLICATION NO. |  |
|  |                       | PCT/FR00/01857   |                               |  |
| 22850<br>OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC |                       | I.A. FILING DATE | PRIORITY DATE                 |  |
|  |                       | 06/30/2000       | 07/01/1999                    |  |

22850
OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC
FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

CONFIRMATION NO. 4236
371 FORMALITIES LETTER
\*OC0000000008531172\*

Date Mailed: 07/30/2002

## NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- · Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- · Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

OBLUN, SPIVAK, McCLELLAND
MAIER & NEUSTADT, P.C.

DOCKETING DEPT.
Initials/Date Docketed:

Type of Resp(s): Seg List

Due Date(s): 9-30-02


The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items MUST be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the



- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

## PATRICIA A BOOKER

Telephone: (703) 305-3738

## PART 1 - ATTORNEY/APPLICANT COPY

| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY. DOCKET NO. |
|-----------------------------|-------------------------------|------------------|
| 10/019,439                  | PCT/FR00/01857                | 217415US0PCT     |

FORM PCT/DO/EO/905 (371 Formalities Notice)